Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

PURPOSE: Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North Central Cancer Treatm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Perez, Edith A., Romond, Edward H., Suman, Vera J., Jeong, Jong-Hyeon, Davidson, Nancy E., Geyer, Charles E., Martino, Silvana, Mamounas, Eleftherios P., Kaufman, Peter A., Wolmark, Norman
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3164242/
https://ncbi.nlm.nih.gov/pubmed/21768458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.0868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados